Volume 95 Issue 10 | p. 15 | Concentrates
Issue Date: March 6, 2017

BMS teams with Grail on cancer detection

Department: Business
Keywords: sequencing, Bristol-Myers Squibb, Grail, cancer

Bristol-Myers Squibb has undertaken a research collaboration with Grail, a computer-based DNA-sequencing firm specializing in cancer detection, aimed at developing blood tests that detect cancer in early stages. BMS will gain access to the company’s clinical trial database as a resource in understanding tumor genomics. BMS, along with Johnson & Johnson, Celgene, and others, has invested $900 million in Grail’s series B fundraising round. Grail expects to raise more than $1 billion to advance cancer blood testing before the latest round closes.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment